Syntara Reports $18M Cash, EHA 2025 Data for SNT-5505, and New Scar Drug Trial
Syntara Limited reports significant clinical progress with its lead myelofibrosis drug SNT-5505 and launches a new trial for its next-generation anti-fibrotic skin treatment, supported by a solid $18 million cash reserve.
- SNT-5505 myelofibrosis interim data accepted for EHA 2025 presentation
- Phase 1a/b trial launched for next-gen topical anti-fibrotic SNT-9465 targeting hypertrophic and keloid scars
- Imaging from SOLARIA2 trial shows structural normalization of scars with SNT-6302
- Strong cash balance of $18 million supports ongoing clinical programs
- Ongoing payment dispute with Arna Pharma over mannitol respiratory business sale
Clinical Progress in Myelofibrosis
Syntara Limited (ASX: SNT) has marked a pivotal quarter with its lead candidate SNT-5505, a novel pan-lysyl oxidase inhibitor targeting myelofibrosis, a debilitating bone marrow cancer. The latest interim data from its Phase 2 trial, evaluating SNT-5505 in combination with ruxolitinib, has been accepted for presentation at the prestigious European Hematology Association (EHA) Congress in June 2025. This follows encouraging early results showcased at ASH 2024 and peer-reviewed publication of Phase 2a monotherapy data in Haematologica, which highlighted tolerability and preliminary efficacy including reductions in bone marrow collagen.
The EHA presentation is expected to provide a substantial data update, reinforcing Syntara’s position in the competitive myelofibrosis landscape. CEO Gary Phillips emphasized the strategic timing, noting the alignment with additional trial data and the opportunity to engage the global hematology community.
Expansion of Skin Scarring Program
Building on its fibrosis expertise, Syntara has accelerated its skin scarring portfolio with the launch of a Phase 1a/b clinical trial for SNT-9465, a next-generation topical anti-fibrotic drug designed for hypertrophic and keloid scars. This program aims to improve patient outcomes by enabling daily application, a significant advancement over current treatments requiring frequent clinical interventions such as steroid injections or laser therapy.
The trial will initially assess safety and tolerability in healthy volunteers before moving to an open-label study targeting scars less than two years old. Results expected in the first half of 2026 will inform potential FDA Investigational New Drug (IND) submissions and global development plans. This initiative leverages insights from the SOLARIA2 trial, where the first-generation compound SNT-6302 demonstrated significant collagen reduction and structural improvements in mature scars, validated by advanced Optical Coherence Tomography imaging.
Innovative Imaging Validates Scar Remodeling
New imaging analysis from the SOLARIA2 trial subgroup has provided compelling evidence that SNT-6302 treatment remodels established scars to more closely resemble normal skin architecture. Using non-invasive OCT technology, treated scars showed marked improvements in vascularization and extracellular matrix structure compared to placebo, a landmark finding in scar therapy development. These results reinforce the scientific rationale behind Syntara’s topical pan-LOX inhibitors and support the clinical advancement of SNT-9465.
Financial Position and Corporate Updates
Despite ongoing market volatility, Syntara maintains a robust cash position of $18 million at quarter-end, supported by proceeds from a recent capital raise and the partial sale of its mannitol respiratory business unit. Operating cash outflows have moderated slightly, with R&D and staff costs comprising the majority of expenditure. However, uncertainty remains regarding the timing and amount of outstanding payments from Arna Pharma, the acquirer of the respiratory business, which continues to be a focus for management.
On the corporate front, Syntara appointed Cameron Billingsley as Company Secretary, succeeding David McGarvey after over two decades of service. This change signals a refreshed governance structure as the company advances its clinical pipeline.
Looking Ahead
Beyond myelofibrosis and skin scarring, Syntara continues to progress its Phase 2a study of SNT-4728 for isolated REM sleep behavior disorder (iRBD), a condition linked to Parkinson’s disease risk. Recruitment has been boosted by the opening of a new UK site at Oxford University, with results anticipated in the first half of 2026. CEO Gary Phillips highlighted these diverse programs as evidence of Syntara’s commitment to addressing fibrosis and inflammation across multiple therapeutic areas.
Bottom Line?
Syntara’s clinical momentum and financial resilience position it well for upcoming data milestones that could redefine fibrosis treatment paradigms.
Questions in the middle?
- How will the detailed EHA 2025 data impact SNT-5505’s regulatory and commercial trajectory?
- What are the prospects for SNT-9465’s global development and potential partnerships following Phase 1 results?
- How will the resolution of the Arna Pharma payment dispute affect Syntara’s cash flow and operational flexibility?